ASX:ANP Antisense Therapeutics (ANP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Antisense Therapeutics Stock (ASX:ANP) 30 days 90 days 365 days Advanced Chart Get Antisense Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.32 million shsAverage VolumeN/AMarket CapitalizationA$52.29 millionP/E RatioN/ADividend Yield4.58%Price TargetN/AConsensus RatingN/A Company Overview Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia. Read More Receive ANP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antisense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANP Stock News HeadlinesANP leader Maulana Khan Zeb among three killed in Bajaur shootingJuly 11 at 9:37 AM | msn.comANP leader, cop gunned down in BajaurJuly 11 at 9:37 AM | msn.com3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. July 12 at 2:00 AM | Timothy Sykes (Ad)ANP leader among three killed in Bajaur shootingJuly 11 at 9:37 AM | msn.comANP chief decries 'shameful' seats verdictJuly 6, 2025 | msn.comANP demands FIR against KP CM on Swat tragedyJune 29, 2025 | msn.comUnexpected bacterial blocker: Antisense molecules inhibit oral Fusobacterium species linked to cancer progressionApril 29, 2025 | msn.comANP extends BW Energy’s Golfinho licence production phase to 2042April 3, 2025 | msn.comSee More Headlines ANP Stock Analysis - Frequently Asked Questions How were Antisense Therapeutics' earnings last quarter? Antisense Therapeutics Limited (ASX:ANP) announced its earnings results on Wednesday, February, 27th. The company reported $0.00 earnings per share (EPS) for the quarter. Antisense Therapeutics had a negative net margin of 720.31% and a negative trailing twelve-month return on equity of 73.14%. What other stocks do shareholders of Antisense Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Antisense Therapeutics investors own include Tocagen (TOCA), Miragen Therapeutics (MGEN), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Iovance Biotherapeutics (IOVA), Genocea Biosciences (GNCA), Capricor Therapeutics (CAPR) and Applied DNA Sciences (APDN). Company Calendar Last Earnings2/27/2019Today7/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryConsumer Goods Current SymbolASX:ANP CIKN/A Webwww.antisense.com.au Phone61 3 9827 8999FaxN/AEmployees5,500Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$11.38 million Net Margins-720.31% Pretax MarginN/A Return on Equity-73.14% Return on Assets-41.69% Debt Debt-to-Equity Ratio1.42 Current Ratio4.51 Quick Ratio18.16 Sales & Book Value Annual SalesA$1.58 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.18 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares901,550,000Free FloatN/AMarket CapA$52.29 million OptionableNot Optionable Beta1.06 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (ASX:ANP) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antisense Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Antisense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.